Antisense-Oligonucleotide Mediated Exon Skipping in Activin-Receptor-Like Kinase 2: Inhibiting the Receptor That Is Overactive in Fibrodysplasia Ossificans Progressiva

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Shi, SongTing ^a   Cai, Jie ^a   de Gorter, David J J ^a,b   Sanchez Duffhues, Gonzalo ^a   Kemaladewi, Dwi U ^a   Hoogaars, Willem M H ^a   Aartsma Rus, Annemieke ^a   't Hoen, Peter A C ^a   ten Dijke, Peter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 2; ANTISENSE OLIGONUCLEOTIDE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 6; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ALK2 GENE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG SELECTIVITY; ENDOTHELIUM CELL; EXON SKIPPING; GENE; GENE EXPRESSION; GENE SILENCING; MOUSE; MUSCLE DEVELOPMENT; NONHUMAN; OSSIFYING MYOSITIS; OSTEOBLAST; RNA SPLICING; SIGNAL TRANSDUCTION;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; BONE MORPHOGENETIC PROTEIN 6; CELL DIFFERENTIATION; EXONS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; HUMANS; MICE; MUSCLE CELLS; MUTATION; MYOBLASTS; MYOSITIS OSSIFICANS; OLIGONUCLEOTIDES, ANTISENSE; OSTEOBLASTS; OSTEOGENESIS; SIGNAL TRANSDUCTION;

EID: 84879805386     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069096     Document Type: Article

References (39)

1. Schlange T, Andree B, Arnold HH, Brand T, (2000) BMP2 is required for early heart development during a distinct time period. Mech Dev 91: 259-270.
2. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, et al. (2009) Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 41: 478-481.
3. Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S, et al. (2006) BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 38: 1424-1429.
4. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, et al. (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38: 525-527.
5. van Dinther M, Visser N, de Gorter DJ, Doorn J, Goumans MJ, et al. (2010) ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res 25: 1208-1215.
6. Shi S, de Gorter DJ, Hoogaars WM, t Hoen PA, Ten Dijke P (2012) Overactive bone morphogenetic protein signaling in heterotopic ossification and Duchenne muscular dystrophy. Cell Mol Life Sci.
7. Cai J, Pardali E, Sanchez-Duffhues G, ten Dijke P, (2012) BMP signaling in vascular diseases. FEBS Lett 586: 1993-2002.
8. Groppe JC, Wu J, Shore EM, Kaplan FS, (2011) In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs 194: 291-295.
9. Song GA, Kim HJ, Woo KM, Baek JH, Kim GS, et al. (2010) Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J Biol Chem 285: 22542-22553.
10. Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, et al. (2008) Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol 22: 191-205.
11. de Gorter DJ, Jankipersadsing V, Ten Dijke P, (2012) Deregulated bone morphogenetic protein receptor signaling underlies fibrodysplasia ossificans progressiva. Curr Pharm Des 18: 4087-4092.
12. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, et al. (2008) BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 14: 1363-1369.
13. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, et al. (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4: 33-41.
14. Yu PB, Deng DY, Beppu H, Hong CC, Lai C, et al. (2008) Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. J Biol Chem 283: 3877-3888.
15. Kaplan J, Kaplan FS, Shore EM, (2012) Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting. Gene Ther 19: 786-790.
16. Takahashi M, Katagiri T, Furuya H, Hohjoh H, (2012) Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva. Gene Ther 19: 781-785.
17. Aartsma-Rus A, van Ommen GJ, (2007) Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13: 1609-1624.
18. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686.
19. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
20. Spitali P, Aartsma-Rus A, (2012) Splice modulating therapies for human disease. Cell 148: 1085-1088.
21. Larsson J, Goumans MJ, Sjostrand LJ, van Rooijen MA, Ward D, et al. (2001) Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J 20: 1663-1673.
22. Walter-Yohrling J, Morgenbesser S, Rouleau C, Bagley R, Callahan M, et al. (2004) Murine endothelial cell lines as models of tumor endothelial cells. Clin Cancer Res 10: 2179-2189.
23. Yamashita T, Ishii H, Shimoda K, Sampath TK, Katagiri T, et al. (1996) Subcloning of three osteoblastic cell lines with distinct differentiation phenotypes from the mouse osteoblastic cell line KS-4. Bone 19: 429-436.
24. Shi S, Hoogaars WM, de Gorter DJ, van Heiningen SH, Lin HY, et al. (2011) BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model. Neurobiol Dis 41: 353-360.
25. Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, et al. (2009) Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 30: 379-390.
26. Aartsma-Rus A, Houlleberghs H, van Deutekom JC, van Ommen GJ, t Hoen PA, (2010) Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing. Oligonucleotides 20: 69-77.
27. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, et al. (1994) Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 127: 1755-1766.
28. Lounev VY, Ramachandran R, Wosczyna MN, Yamamoto M, Maidment AD, et al. (2009) Identification of progenitor cells that contribute to heterotopic skeletogenesis. J Bone Joint Surg Am 91: 652-663.
29. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, et al. (2010) Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 16: 1400-1406.
30. Leblanc E, Trensz F, Haroun S, Drouin G, Bergeron E, et al. (2011) BMP-9-induced muscle heterotopic ossification requires changes to the skeletal muscle microenvironment. J Bone Miner Res 26: 1166-1177.
31. Dang ZC, van Bezooijen RL, Karperien M, Papapoulos SE, Lowik CW, (2002) Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. J Bone Miner Res 17: 394-405.
32. de Gorter DJ, van Dinther M, Korchynskyi O, ten Dijke P, (2011) Biphasic effects of transforming growth factor beta on bone morphogenetic protein-induced osteoblast differentiation. J Bone Miner Res 26: 1178-1187.
33. Aartsma-Rus A, van Vliet L, Hirschi M, Janson AA, Heemskerk H, et al. (2009) Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17: 548-553.
34. Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, et al. (2004) Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther 11: 1391-1398.
35. Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, et al. (1999) Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci 112 (Pt 20): 3519-3527.
36. Lavery K, Swain P, Falb D, Alaoui-Ismaili MH, (2008) BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. J Biol Chem 283: 20948-20958.
37. Chakkalakal SA, Zhang D, Culbert AL, Convente MR, Caron RJ, et al. (2012) An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. J Bone Miner Res 27: 1746-1756.
38. Oberbauer R, Schreiner GF, Meyer TW, (1995) Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int 48: 1226-1232.
39. Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, et al. (2002) Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 12Suppl 1: S71-77.